Erschienen in:
01.06.2015 | Understanding the Disease
Understanding the benefits and harms of oxygen therapy
verfasst von:
Pierre Asfar, Mervyn Singer, Peter Radermacher
Erschienen in:
Intensive Care Medicine
|
Ausgabe 6/2015
Einloggen, um Zugang zu erhalten
Excerpt
The Dr. Jekyll and Mr. Hyde character of oxygen (O
2) is well established [
1], with O
2 the vital final electron acceptor within the respiratory chain, but also a strong oxidizer that leads to the formation of “reactive oxygen species” (ROS). Hyperoxia-related increases in ROS production are particularly pronounced during ischaemia/reperfusion (I/R) and hypoxia/reoxygenation [
2]. This dichotomy also holds true for ATP synthesis and ROS formation. Approximately 2 % of mitochondrial O
2 consumption is directed towards ROS production, i.e., the more ATP produced, the more ROS generated [
2]. ROS also share friend-and-foe characteristics, in that despite their toxic potential they are vital players in host defence systems and as signaling molecules [
3]. …